Constitutive mTORC1 Activation in Skeletal Muscle Increases Inflammation but is not Sufficient to Impair Glucose Tolerance.

Marchant ED, Kalenta H, Kilroe SP, May J, Martini WZ, Weldon KS, Lai Z, Rasmussen BB · 2026 · Function (Oxford, England) · Atlas ID MARCHANT2026

What this study shows

Constitutive mTORC1 activation in mouse skeletal muscle (via GATOR1 complex KO) increases inflammatory markers but is not sufficient to impair glucose tolerance, indicating that additional metabolic inputs beyond muscle mTORC1 hyperactivation are required to drive glucose intolerance.

Abstract

ShowHide

Aberrant mTORC1 signaling in skeletal muscle has been implicated in aging and insulin resistance, however, it is not known whether chronic mTORC1 activation directly causes glucose intolerance. We tested the hypothesis that constitutive mTORC1 activation in mouse skeletal muscle impairs glucose homeostasis using tamoxifen-inducible, muscle-specific GATOR1 complex knockout.

Read the full abstract on PubMed →

At a glance

Evidence type	A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Mouse); the code names the system studied -- animal work can be rigorous and still not be human data.
Study type	4 - Animal Study
Model system	Mouse
Journal	Function (Oxford, England)
Year	2026
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1152/function.039.2026 · PMID 42468920 · Free full text (PMC13459988)

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Constitutive mTORC1 activation (GATOR1 muscle-specific KO)
Target	mTORC1 / GATOR1 complex
Model	Mouse
Effect	Increased skeletal muscle inflammation without impairment of glucose tolerance

In the Atlas

Open questions that cite this study

Cited as supporting evidence for the open question Does mTORC1-selective dosing extend lifespan, and is rapamycin's glucose intolerance a cost at all?.

Cite this paper

ShowHide

Marchant, E. D., Kalenta, H., Kilroe, S. P., May, J., Martini, W. Z., Weldon, K. S., Lai, Z., & Rasmussen, B. B. (2026). Constitutive mTORC1 Activation in Skeletal Muscle Increases Inflammation but is not Sufficient to Impair Glucose Tolerance. Function (Oxford, England). https://doi.org/10.1152/function.039.2026

@article{MARCHANT2026,
  author       = {Marchant, E. D. and Kalenta, H. and Kilroe, S. P. and May, J. and Martini, W. Z. and Weldon, K. S. and Lai, Z. and Rasmussen, B. B.},
  title        = {{Constitutive mTORC1 Activation in Skeletal Muscle Increases Inflammation but is not Sufficient to Impair Glucose Tolerance}},
  journal      = {Function (Oxford, England)},
  year         = {2026},
  doi          = {10.1152/function.039.2026},
  note         = {PMID: 42468920},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record MARCHANT2026) [Data set]. https://mtor-atlas.org/study/MARCHANT2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_MARCHANT2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record MARCHANT2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/MARCHANT2026/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?